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ABSTRACT  28 
The genomes of the Reoviridae, including the animal pathogen Bluetongue virus (BTV), are 29 
multi-segmented double-stranded (ds) RNA. During replication, single-stranded (ss) positive-30 
sense RNA segments are packaged into the assembling virus capsid, triggering genomic 31 
dsRNA synthesis. However, exactly how this packaging event occurs is not clear. A minor 32 
capsid protein VP6, unique for the orbiviruses, has been proposed to be involved in the RNA 33 
packaging process. In this study, we sought to characterize the RNA binding activity of VP6 34 
and its functional relevance.  A novel proteomic approach was utilized to map the ss/dsRNA 35 
binding sites of a purified recombinant protein and the genomic dsRNA binding sites of the 36 
capsid-associated VP6. The data revealed each VP6 has multiple distinct RNA binding 37 
regions and only one region is shared between recombinant and capsid-associated VP6. A 38 
combination of targeted mutagenesis and reverse genetics identified the RNA-binding region 39 
that is essential for virus replication. Using an in vitro RNA-binding competition assay, a 40 
unique cell-free assembly assay and an in vivo single cycle replication assay, it was possible 41 
to identify a motif within the shared binding region that binds BTV ssRNA preferentially 42 
consistent with specific RNA recruitment during capsid assembly. These data highlight the 43 
critical roles this unique protein plays in orbivirus genome packaging and replication.  44 
 45 
Importance  46 
Genome packaging is a critical stage during virus replication. For virus with segmented 47 
genome, the genome segments need to be correctly packaged into a newly formed capsid. 48 
However, the detailed mechanism of this packaging is unclear. Here we focus on VP6, a 49 
minor viral protein of Bluetongue virus, which is critical for genome packaging. We use 50 
multiple approaches including a robust RNA-protein finger-printing assay, which map the 51 
ssRNA binding sites of recombinant VP6 and the genomic dsRNA binding sites of the 52 
capsid-associated VP6. Together with virological and biochemical methods, within VP6, we 53 
for the first time identify the viral RNA packaging motif of a segmented dsRNA virus.  54 
 55 
Keywords: Genome packaging/RNA-protein interaction/dsRNA virus 56 
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INTRODUCTION 58 
Bluetongue virus (BTV) is an important animal pathogen and the prototype of the Orbivirus, 59 
a genus of the Reoviridae family. The BTV particle has two capsids, an outer capsid and an 60 
inner capsid, the latter of which is also called the core. The outer capsid contains proteins 61 
VP2 and VP5 to facilitate virus entry through the cellular membrane and the release of the 62 
core into the cytoplasm. The icosahedral-shaped core is principally comprised of two 63 
proteins, VP7 and VP3, which are arranged in two layers. The VP3 encloses the viral 64 
genome of ten double-stranded RNA (dsRNA) segments (S1-S10). In addition, the core 65 
contains three minor proteins: the polymerase (VP1), the capping enzyme (VP4), and VP6, 66 
an essential structural protein of 36 kDa with RNA binding and ATP binding activity. VP6 is 67 
unique among the Orbivirus genus within the Reoviridae family. 68 
 69 
Upon entry, core particles become transcriptionally active, producing and extruding single-70 
stranded positive-sense RNAs (ssRNA) through the local channels at the five-fold axis, 71 
without further disassembly. These ssRNAs then act both as mRNAs for viral protein 72 
synthesis, and as templates for nascent genomic RNA synthesis. Our current understanding 73 
is that the newly synthesised 10 ssRNA segments are first combined via specific 74 
intersegment RNA-RNA interactions to form RNA complexes of all 10 segments. The RNA 75 
complexes of 10 segments are then packaged together with VP1, VP4 and VP6, into the 76 
assembling VP3 capsid layer (1-4). Genomic dsRNA molecules are subsequently 77 
synthesized within this assembled particle (known as the ‘subcore’), prior to encapsidation 78 
by the VP7 layer, leading to a robust core particle formation (5).  79 
 80 
VP1 polymerase and capping enzyme VP4 are likely to be located beneath the VP3 layer at 81 
or near the five-fold axis of icosahedral symmetry to facilitate the release of newly 82 
synthesised transcripts (6, 7). However, the exact location of VP6 is not yet clear, although 83 
VP6 has specific binding affinity for VP3 and this interaction has been shown to be important 84 
for viral ssRNA packaging and replication (8). Using reverse genetics (RG), we have shown 85 
that VP6 is essential for BTV replication and that modified BTV strains lacking VP6 do not 86 
replicate in normal cells but only in a VP6 helper cell line (9). Further, when VP6-deficient 87 
viruses were grown in VP6 helper cells and used for infection of normal cells, viral proteins 88 
are synthesized and assemble as empty particles without the viral genome. This data 89 
suggests that VP6 may be responsible for genome packaging (10, 11).  90 
 91 
The smallest core associated protein, VP6 (328 aa), has high binding affinity for both ssRNA 92 
and dsRNA species, suggesting that it is closely associated with the viral genome (12, 13). 93 
VP6 was previously suggested to be an RNA helicase, despite poor homology with known 94 
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helicases (14). Current hypothesis is that VP6 assists in ssRNA packaging into the viral core 95 
through the interaction with VP3 (1, 8, 15). However, questions concerning the definition of 96 
the sites that bind viral ssRNAs, whether this is specific over cellular RNAs and how VP6 97 
interacts with genomic dsRNA, remain to be addressed. 98 
 99 
In this study, we used RNA crosslinking and peptide fingerprinting (RCAP) to identify the 100 
RNA binding sites of VP6 using both a recombinant VP6 protein (reVP6) and in purified viral 101 
cores. The data demonstrate that multiple regions of reVP6 and core associated VP6 102 
interact with both ssRNA and dsRNA but that each source of VP6 had a largely unique RNA 103 
binding profile with only one region in common. Mutagenesis of residues within the mapped 104 
RNA-binding regions followed by virus recovery using the RG system demonstrated that the 105 
VP6-RNA binding regions of the core associated VP6 were essential for BTV replication 106 
while those associated with reVP6 were dispensable. Within the essential binding sites, 107 
residues that recognize BTV RNA preferentially, possibly necessary for genome recruitment 108 
and packaging were identified. This study highlights the essential role of the orbivirus protein 109 
VP6 in genome packaging and replication.  110 
 111 
  112 
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 113 
MATERIAL AND METHODS 114 
Virus, plasmids, mutagenesis and RNA transcripts synthesis 115 
BTV-10 VP6 was used for the mutational analysis and reverse genetics (14, 16). BTV-1 116 
(Genbank accession numbers FJ969719-FJ969728), which VP6 is fully exchangeable with 117 
BTV-10, was used in RCAP for viral capsids. All mutations of VP6 were generated by site-118 
directed mutagenesis, sequences of these mutations and primers are available upon 119 
request. Transcripts for reverse genetic analyses were prepared using mMACHINE T7 120 
transcription kit (Thermo); RNA transcripts for gel shifting and competition assay were 121 
prepared using T7 polymerase (Thermo), following manufacturers’ instructions.  122 
 123 
Recombinant VP6 (reVP6) expression and purification 124 
The expression and purification of BTV-10 reVP6 using baculovirus in the Sf9 cell line was 125 
described previously (14).  Additionally, His tagged wild-type (WT) and mutant reVP6 126 
proteins were expressed in the E. coli strain BL21 (DE3) pLysS. The His-tagged reVP6 127 
proteins were purified using Ni-NTA nickel affinity purification eluting the purified protein with 128 
buffer comprising 20 mM Tris-HCl, 200 mM NaCl, pH 7.4, and 250 mM imidazole. Imidazole 129 
was then removed by buffer exchange Sephadex G-75 columns (GE Healthcare). 130 
 131 
RCAP  132 
The RCAP assay was done as described previously (17, 18). For analysis of recombinant 133 
VP6 binding to RNA, one mole of RNA was added to two moles of recombinant protein. The 134 
molar ratio of RNA was kept low to decrease non-specific protein crosslinking to RNA.  135 
Formaldehyde was then added to a final concentration of 0.1% and incubated for 10 min at 136 
room temperature. Glycine was added to a concentration of 0.2 M for 10 min to quench 137 
additional crosslinking. The crosslinked protein-RNA complexes were digested using 138 
sequencing-grade trypsin (Trypsin Gold, Promega) for 16 h using a 1:20 (w/w) ratio of trypsin 139 
to capsid. RNA-peptide complexes were then selectively precipitated using a final 140 
concentration of 3 M lithium chloride and centrifugation at 16,000 x g. The peptide-RNA 141 
conjugates were reversed by a 1 h incubation at 70oC. Parallel control reactions to assess 142 
background signals were performed without the addition formaldehyde or, in the case of the 143 
recombinant protein, without RNA. RCAP peptides were analysed using an Orbitrap Elite 144 
hybrid ion trap mass spectrometer equipped with an electrospray ionization source 145 
(ThermoFisher Scientific). The peptides were resolved using a Dionex UltiMate 3000 HPLC 146 
with a 1 x 150 mm Zorbax 300SB-C18 column (Agilent) and eluted using a linear gradient of 147 
2–45% acetonitrile in water with 0.1% formic acid over 90 minutes with a flow rate of 50 148 
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µl/min.  Tandem mass spectra were obtained using collision-induced dissociation in a data-149 
dependent manner. Raw mass spectral data files were converted to mascot generic format 150 
and analysed using SearchGUI (19).  Spectra were searched against a database of BTV 151 
proteins concatenated with the cRAP database (20).  Unspecific enzyme cleavage and a 152 
mass tolerance of 10 ppm were used.  Search results were compiled and visualized using 153 
PeptideShaker (21), and results were exported as a CSV file for automated processing with 154 
custom KNIME workflows (22).  155 
 156 
Immunofluorescence staining and confocal microscopy 157 
BSR cells transfected with 800 ng of VP6 capped S9 RNA containing wild type and mutant 158 
VP6 together with 800 ng of NS2 encoding capped S8 RNA by using Endofectin 159 
(GeneCopoeia), according to the manufacturer’s instructions. 24 h post transfection cells 160 
were fixed with 4% paraformaldehyde (Sigma) solution, permeabilized with 0.5 % Triton 161 
X100 (Sigma), blocked with 1% BSA (Bovine Serum Albumin, Sigma), and subsequently 162 
stained using rabbit anti-NS2 and guinea pig anti-VP6 homemade primary antibodies, and 163 
anti-rabbit Alexa 546 and anti-guinea pig Alexa 488 coupled secondary antibodies (Thermo 164 
Fisher Scientific). Nuclei were stained using Hoechst 33342 (Thermo Fisher Scientific). 165 
Images were acquired using an x100 oil objective and a Zeiss Axiovert LSM510 confocal 166 
microscope supplied with the LSM510 software. 167 
 168 
Circular dichroism (CD) spectra of reVP6 169 
The CD spectra of reVP6 were recorded in CD buffer (20 mM Na2HPO4, 100mM NaCl, pH 170 
7.4) at 20 °C. The far UV CD Spectral data were collected from 260–195 nm with a 0.5 mm 171 
rectangular cell path length at 20 °C on the Applied Photophysics Chirascan & Chirascan 172 
Plus spectrometers (Leatherhead, UK) attached to a Peltier unit (Quantum NorthWest 173 
TC125). The UV & CD spectra were smoothed (window factor of 4, Savitzky-Golay method) 174 
and analysed using Origin V6 and APL Prodata Viewer v4.2.15. The estimate of percentage 175 
secondary structural units (alpha helix and beta strand) of protein from the experimental CD 176 
spectra was calculated using K2D3 program as previously described (23).   177 
 178 
Electrophoretic mobility shift assay (EMSA) using 32P-labelled RNA 179 
RNA labelling and the EMSA were performed as described previously (24). A typical binding 180 
assay of 20 µL contains 3 µg of reVP6 in the RNA binding buffer (2 mM MgCl2, 60 mM KCl, 181 
100 mM NaCl, 20 mM Hepes, pH 7.5, 10% glycerol, 1 unit of RNasin (Promega)). 182 
Radiolabelled BTV S10 was heated to 65°C for 2 min, the mixture of VP6 in binding buffer 183 
was added and incubated for 30 min at 4°C. Samples were then analysed on 0.8% agarose 184 
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gels in TBE (Tris borate-EDTA; 89 mM Tris, pH 7.4, 89 mM boric acid, 2.5 mM EDTA). The 185 
gels were dried and analysed by autoradiography or using Amersham Biosciences 186 
PhosphorImager. For competition assay, 18 nM of radiolabelled S10 RNA was incubated 187 
with 4 µM of reVP6 in presence of 1, 3, or 6 µg (85, 255, or 510 nM) of non-specific Xenopus 188 
elongation factor mRNA (Thermo Scientific). The mixture was analyzed as described. 189 
 190 
Reverse genetics 191 
Mutations in the cDNA of S9 RNA that encodes VP6 were generated using site-directed 192 
mutagenesis  mutations (sequences available upon request), together with the other 9 BTV 193 
genome segments that were used to transfect BSR cells or a BSR cell line that stably 194 
expresses VP6 (BSR-VP6), as described by Boyce et al. (25). CPE was monitored after 3 195 
days and the mutations in S9 in the recovered viruses was confirmed by RT-PCR and 196 
sequencing.  197 
 198 
Plaque assay 199 
WT and mutant viruses were diluted and applied to BSR cell monolayers at 0.01 to 0.1 MOI, 200 
covered by Avicel overlayers as described by Matrosovich et al. (26). Cells were fixed with 201 
formaldehyde and the plaque size monitored after 3 days.  202 
 203 
Single cycle replication assay  204 
WT BTV, VP6 truncated virus, and VP6 mutant viruses, were used to infect BSR cells or 205 
BSR cells that stably express VP6 (BSR-VP6). The cells were harvested at 12 hr post 206 
infection (hpi) and viral particles purified as described previously by Matsuo et al. (11). The 207 
purified virus was treated with RNaseA to remove non-packaged RNA. The RNA was 208 
extracted using a viral RNA purification kit (Thermo Fisher Scientifics). The positive and 209 
negative-sense RNA, representing genomic ssRNA and dsRNA respectively, were 210 
measured by qRT-PCR using viral RNA-specific primers (sequences available upon request) 211 
(27). To measure dsRNA synthesis, cell lysate at different time points were collected, 212 
immediately frozen in -80°C, and the quantity of ssRNA and dsRNA in the cell lysate were 213 
similarly measured with qRT-PCR. 214 
 215 
In vitro cell-free assembly (CFA) assay 216 
The BTV in vitro assembly assay has been described previously (5). Briefly, the ten 217 
segments of ssRNA were incubated with VP1, VP4 and VP6, for 30 min, followed by adding 218 
VP3 and VP7 sequentially with a 1.5 hr incubation after each addition. As controls, the VP6 219 
protein was either left out of the assembly reaction, or added after VP3. To avoid the VP6 220 
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protein being translated from the S9 of the ten ssRNAs, we used a vaccine strain S9 RNA, 221 
which does not translate VP6. The samples were then subjected to a 15%-65% sucrose 222 
gradient and the packaged RNA quantified with qRT-PCR. 223 
 224 
RNA binding assay 225 
5 µg of purified WT or mutant His-tag VP6 were bound with 30 µl of Ni-NTA agarose beads 226 
(Thermo) in a buffer of 150 mM NaCl and 40 mM Tris-HCl pH 8.0. The protein-coated beads 227 
were then incubated with 0.3 µg (1.1 pmol) of BTV S10 RNA in the presence or absence of 228 
30 µg (1 nmol) of yeast tRNA. After extensive washes, the bound RNA was eluted by 229 
heating and quantified by qRT-PCR. 230 
 231 
qRT-PCR 232 
The extracted viral RNA from the single cycle replication and CFA assay was subjected to 233 
RT reaction, using specific BTV S6 forward or reverse primers, followed by qPCR, using 234 
SYBR-Green master mix (Labtech) and S6 primers (27). RNA eluted from VP6-RNA beads 235 
binding assay was quantified using specific BTV S10 primers. 236 
  237 
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RESULTS 238 
Genomic ssRNA is not packaged in the viral capsid in the absence of VP6  239 
During BTV replication, newly synthesised ssRNA segments are first packaged into the 240 
assembling viral cores, which in turn serve as templates for the synthesis of genomic dsRNA 241 
segments (5). VP6 has been shown to be an essential component of the primary replication 242 
complex and has been hypothesized to function in recruiting and packaging BTV RNA (9, 243 
10, 13). Rescued BTV carrying a truncated VP6 was only possible in a VP6 complementary 244 
cell line and although these rescued VP6-defective viruses could express BTV proteins on 245 
infection, they assembled only a low level of particles, which lacked the viral genome as 246 
visualized by electron microscopy (11). To confirm correlation between a functional VP6 and 247 
RNA packaging, an available BTV strain with a truncated VP6 (triple stop codons introduced 248 
at residues 87-89 (28)) was grown in a VP6-complementing BSR-derived cell line (BSR-249 
VP6) and, after 3 days, the recovered virion particles were used to infect both parental BSR 250 
cells and BSR-VP6 cells. Although these particles lacked the S9 RNA segment that encodes 251 
VP6, they still contained VP6 protein incorporated from BSR-VP6 cells used to recover the 252 
virus and thus were capable of synthesizing first round ssRNAs, although not capable of 253 
completion of replication or second round transcription following infection of WT BSR cells.  254 
Newly synthesised viral particles were harvested after 12 hours, the result of only one 255 
replication cycle. The packaged RNA was quantified by qRT-PCR, assaying for both positive 256 
and negative strands of S6 RNA with a S6 RNA segment-specific probe. While both the 257 
positive and negative strands of RNA molecules were present in the particles recovered from 258 
BSR-VP6 cells, particles from normal cells had less than 3% of the amount observed in the 259 
BSR-VP6 cells grown particles (Figure 1A). This low-level signal is most likely residual RNA 260 
from the inoculum. These data confirm that in the absence of functional VP6 newly 261 
synthesized viral RNA segments are not packaged, consistent with a role in the packaging of 262 
viral RNA. As a control, we measured the BTV ssRNA in the cell lysate from BSR-VP6 or 263 
BSR cells infected with VP6-truncated particles (Figure 1B). BTV ssRNA transcripts were 264 
synthesized abundantly in both cell lines, slightly more so in BSR-VP6 cells than the WT 265 
BSR cells.  266 
 267 
To investigate at which stage VP6 can affect virus assembly, we used the established in 268 
vitro cell-free assembly (CFA) assay (5). In this assay, the ten ssRNA segments of BTV are 269 
first incubated with replicase complex proteins VP1, VP4 and VP6, followed by the 270 
incubation with the inner capsid proteins VP3 and VP7, to assemble a core particle. We 271 
modified this assay for our study by either excluding VP6, or by including it after the addition 272 
of VP3, so that it should not be incorporated into the core particle. The amount of RNA 273 
encapsidated was then quantified using RT-PCR as before. In the absence of VP6, ssRNA 274 
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packaging was reduced to less than 10% of the control (Figure 1C). Further, the addition of 275 
VP6 after VP3, which forms the inner layer of the core, failed to rescue RNA packaging. 276 
These data further suggest that VP6 plays a role in the early stage of genomic ssRNA 277 
packaging prior to inner core assembly. 278 
 279 
Identification of the RNA binding sites of VP6 and their impact on virus replication 280 
VP6 has a high number of charged residues and readily binds non-specific ssRNA and 281 
dsRNA in vitro (16, 29). We sought to identify the RNA binding regions in VP6 using a 282 
proteomic-based RCAP method. For the RCAP analysis, we used S10, the smallest of the 283 
BTV RNA segments and a recombinant VP6 (reVP6) expressed in the baculovirus 284 
expression system. Two independent experiments, each with independent samples 285 
replicated in triplicate, identified very similar RNA binding regions within reVP6 (Figure 2), 286 
indicating that such an approach can reproducibly identify residues that contact RNA. All of 287 
the peptides were not present in reactions lacking RNA and the majority are also absent in 288 
control reactions that were not crosslinked with formaldehyde (Table 1). Three regions of 289 
VP6 were strongly associated with binding ssRNA: aa2-15 (Re1), aa110-141 (Re2) and 290 
aa220-284 (Re3) (Figure 2). To assess whether these in vitro RNA-binding sites are 291 
important for virus replication, six positively-charged sites within VP6 (KR14-5, K110, K131, K141, 292 
KK246-7, RK257-8) were selected for substitution mutagenesis. To perturb the potential RNA 293 
binding affinity, each residue was substituted for glutamic acid (Glu, E), either individually 294 
(K110, R131, R141) or as double substitution mutations (KR14-5, KK246-7, RK257-8). Each of these 295 
mutant segments, together with the other nine WT BTV RNA segments, were then 296 
transfected into BSR cells for virus recovery. 297 
 298 
Mutations in Re1 (KR14-5EE) or Re2 (K110E, R131E, and R141E) did not affect virus recovery; 299 
recovered mutant viruses produced plaques with a similar size to the parental virus (Figure 300 
3A). DNA sequencing confirmed the presence of the mutations within S9 for all recovered 301 
viruses and the absence of compensatory mutations elsewhere. In contrast, the double 302 
mutations located within the RNA binding region Re3 (KK246-7EE and RK257-8EE) prevented 303 
virus recovery despite several independent attempts. To examine this further, two pairs of 304 
negatively-charged residues from a conserved Glu rich motif (EE-K-XX-EE) in the same Re3 305 
region were also mutated to neutral charged glutamine (EE225-6QQ and EE230-1QQ). Both 306 
mutant constructs were then tested for their impact on virus recovery by RG. In both cases, 307 
the virus was successfully recovered, suggesting that positively-charged residues in region 308 
Re3, but not the negatively-charged residues, are important for viral infection. The positively-309 
charged residues located in RNA binding region Re3 are thus essential for virus replication.  310 
 311 
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Although VP6 binds both ssRNA and dsRNA (16) it is not known if the sites concerned are 312 
the same. To investigate this, BTV genomic dsRNA segments were isolated from BTV 313 
infected cells and the RCAP analysis with reVP6 was repeated using dsRNA. The dsRNA-314 
binding regions identified were similar with those that bind ssRNA (Figure 2, Table 1), 315 
suggesting that, in the absence of other viral proteins, VP6 binds ssRNA and dsRNA in a 316 
similar manner.  317 
 318 
Identification of VP6-RNA binding regions within the viral capsid and their importance 319 
on virus replication 320 
Recombinant VP6 has multiple regions that contacts ssRNA and dsRNA. However, VP6 321 
found in the virus cores are in contact with capsid protein and this could impact RNA binding. 322 
To examine this, we purified mature cores and subjected them to RCAP analysis (Figure 2). 323 
Peptides from several core-associated proteins were identified and those from VP6 were 324 
assigned based on collision-induced fragmentation of each peptide.  Within VP6, four 325 
regions were found to contact the encapsidated genomic dsRNA: residues aa151-177 (Ca1), 326 
aa246-257 (Ca2), aa281-300 (Ca3) and aa305-328 (Ca4). Notably, only Ca2 overlaps with 327 
the RNA-binding region 3 found when the analysis was done with reVP6. Thus, core-328 
associated VP6 has a different binding profile to recombinant VP6. To map the essential 329 
binding sites a number of positively-charged residues in the identified Ca regions were 330 
targeted for site-directed mutagenesis and virus recovery using RG system. Five site-331 
specific mutations were introduced, R167E and R177E, located in region Ca1, K296E in region 332 
Ca3, KRR303-5EEE and K318E in region Ca4. Among the five mutations introduced into VP6, 333 
only K318E, permitted recovery of viruses with normal plaque size (Figure 3B). All other 334 
mutations abrogated virus recovery. Consistent with previous data, the two positively-335 
charged sites (KK246-7EE and RK257-8EE) in the Ca2/Re3 shared region (Ca2/Re3) were 336 
lethal confirming these regions as critical for virus replication.  Residues RK208-209  of VP6 337 
that were previously proposed to contact BTV RNA by bioinformatics analysis, were not 338 
identified by RCAP (14). In contrast to the Ca mutants, a RK208-209EE VP6 mutant did not 339 
perturb virus recovery, demonstrating that RCAP is more precise method for recognizing 340 
RNA-contacting residues. 341 
 342 
Previous data has suggested that certain RNA sequences in the BTV genome, especially in 343 
the smaller RNA segments, act as packaging signals that mediate RNA assembly through 344 
RNA-RNA interaction (1, 15). To ensure that the mutations introduced into the S9 RNA 345 
sequence encoding VP6 did not affect RNA packaging, the lethal mutations described above 346 
were also rescued using a RG system in the VP6-complementary BSR-VP6 cells (9). 347 
Viruses with mutations in all six Ca regions produced the virus in BSR-VP6 cells. 348 
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Furthermore, the rescued virus failed to grow when passaged on normal BSR cells. These 349 
results confirmed that the lethal effect of these mutations was due to changes in VP6 350 
protein, not due to a change in the packaging signals in S9 RNA.  351 
 352 
To exclude the concern that substitutions of negatively-charged residues influences protein 353 
conformation or isoelectric point, five lethal mutations were also redesigned to change the 354 
positively-charged R or K into alanine (Ala, A) (R167A, R177A, KK246-7AA, RK257-8AA, and 355 
K296A). None of these mutants was recovered following RG transfection in the normal BSR 356 
cells (data not shown). However, when S9 RNA carrying critical Ca2/Re3 region mutations 357 
(KK246-7EE, RK257-8EE, KK246-7AA and RK257-8AA) were transfected into BSR cells, all the 358 
mutant VP6 expressed in the cells and the localization was not different from WT VP6 359 
(Figure 4).  360 
 361 
To ensure no gross conformational change in the mutation mapped as critical, several 362 
mutant VP6 proteins were expressed in E. coli, purified and analysed by gel electrophoresis 363 
and for secondary structure. Each mutant VP6 exhibited the same mobility as the WT VP6 364 
(Figure 5A) and when analysed by circular dichroism (CD) spectroscopy, all showed similar 365 
spectra except a slight difference with RK208-9EE and KRR303-5EEE compared to the WT. 366 
However, relative values of alpha helix and beta sheet did not vary beyond the variance of 367 
the assay (Figure 5B and Table 2). We calculated the secondary structure elements using 368 
tool K2D3. The change in % of individual secondary structure components clearly showed it 369 
is not significant.  370 
 371 
Taken together, these data suggest that mutations introduced into VP6 to probe its RNA 372 
binding function studied here did not induce major conformational change in any of the 373 
mutants described.   374 
 375 
The lethal VP6 mutant lacks preferential binding affinity for viral RNA 376 
BTV S10 ssRNA was previously found to be critical for efficient RNA packaging (1, 15, 30) 377 
and was therefore used as the source of RNA to investigate the preference of the RNA 378 
binding by VP6. VP6 binding to S10 RNA was examined using 32P-labelled S10 RNA by a 379 
gel electrophoretic mobility shift assay (EMSA). Three recombinant VP6 proteins were 380 
tested, a replication competent mutant, RK208-9EE, a replication incompetent mutant, RK257-381 
8EE, which is located within the Ca2/Re3 region and WT reVP6. In the EMSA, all three 382 
proteins exhibited strong band retardation, plausibly a measure of the non-specific RNA 383 
binding function described above (Figure 6A). To investigate preferential binding by VP6 an 384 
alternate, competition method of RNA-protein interaction was used. S10 ssRNA was 385 
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exposed to Ni-NTA agarose beads coated with His-tagged WT reVP6 or RK257-8EE mutant in 386 
the presence or absence of an excess of yeast tRNA and, after pull-down, the bound RNA 387 
was quantified by qRT-PCR. The amount of RNA bound was not significantly affected in the 388 
presence of excess yeast tRNA for WT reVP6 while for the RK257-8EE mutant the presence 389 
of excess tRNA significantly reduced the level of S10 RNA bound (Figure 6B).  390 
 391 
To confirm this in a quantitative manner, we performed competition assay in presence of 392 
different quantities of non-specific RNA (Figure 7). To exclude the possibility that the 393 
difference in binding was due to small size of the competitor tRNA, we used a longer ssRNA 394 
encoding Xenopus elongation factor 1α as a non-specific RNA. Further, to ensure the RNA 395 
binding was not influenced by changes in charge, we expressed the mutant RK257-8AA in E 396 
coli, purified and utilized for EMSA. The data showed that RK257-8AA reVP6 had much lower 397 
preferential binding with BTV RNA compared to WT reVP6 (Figure 7B). Moreover, when an 398 
additional positively-charged site RK246-7 within the same Ca2/Re3 region, was mutated to 399 
Ala, it also exhibited a significant effect on the preference of VP6 for BTV RNA (Figure 7C). 400 
However, the replication competent mutant, RK208-9EE, exhibited gel shifting patterns similar 401 
to the WT reVP6 (Figure 7D).  These results indicate that the Re3/Ca2 region in VP6 is part 402 
of a preferential BTV RNA binding site. 403 
  404 
Mutant VP6 is unable to package viral RNAs 405 
The Ca2/Re3 region binds both ssRNA in vitro and dsRNA in the viral capsid. Further, it 406 
exhibits preference for BTV RNA, consistent with a key role in the recruitment of ssRNA into 407 
assembling capsids. To confirm this, we employed the in vitro CFA assay, which had already 408 
demonstrated that RNA packaging was dependent on VP6. Making use of the RK257-8EE 409 
VP6 mutant, WT VP6 (positive control) or no VP6 (negative control) the level of incorporated 410 
genomic RNAs in the in vitro assembled cores was measured by qRT-PCR. RNA packaging 411 
was significantly reduced compared to WT when the RK257-8 mutant protein was present, 412 
almost to the background level of incorporation observed in the absence of VP6 (Figure 8). 413 
To assess if a similar effect occurs in infected cells, RK257-8EE mutant virus grown in the 414 
BSR-VP6 helper cell line was used to infect the parental BSR cell line for 6 hrs and total 415 
RNA was extracted from 0 to 6 hpi. As control, BSR-VP6 cells, which are permissive for the 416 
growth of the mutant, were also infected with the same virus preparation and RNA extracted. 417 
All RNA samples were analysed by qRT-PCR using primers specific for the detection of 418 
positive or negative-sense RNA, as previously described. In this analysis quantification of 419 
the negative strand act as a marker for dsRNA synthesis as previously described (5, 11). 420 
During the infected period, a similar quantity of positive-sense BTV-RNA was produced by 421 
the mutant virus in both cell lines. However, in the parental BSR cells negative-sense RNA 422 
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synthesis was reduced to ~1000 folds at 6 hpi, when compared to the parental virus (Figure 423 
9). These data are consistent with VP6 acting in the packaging of BTV RNA into the core via 424 
preferential recognition by the Ca2/Re3 region.  425 
 426 
  427 
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 428 
DISCUSSION 429 
Previous reports have implicated VP6, a protein with clusters of charged residues, in the 430 
packaging of the viral genomic RNA, but precise mapping of the binding sites and their 431 
contribution to virus replication was not reported (8, 11, 13, 14, 16). We used a robust 432 
peptide mapping method, RCAP, which could identify interactions between VP6 and the viral 433 
genome in the natural state leading to the identification of four (Ca) VP6-BTV RNA binding 434 
sites. When compared to binding sites mapped by the binding of recombinant (Re) VP6 to 435 
RNA in vitro, several regions were distinct suggesting that the RNA binding by VP6 contains 436 
both specific and non-specific elements. Mutations in the Ca RNA binding sites targeting 437 
positively-charged residues (R167, R177, KK246-7, RK257-8, K296, and KRR303-5) prevented virus 438 
recovery irrespective of the charge status of the mutated residues. These six sites are highly 439 
conserved among the VP6 of different BTV serotypes and the related orbiviruses EHDV and 440 
AHSV. This suggests the interaction between VP6 and RNA within the core is invariant 441 
consistent with a key functional role.  442 
 443 
More recently, a specific site of VP6 (aa276-287) was reported to interact with the inner layer 444 
capsid protein VP3, an interaction that was essential for virus assembly (8). This interaction 445 
site is distinct from the RNA interaction sites reported here suggesting it may act to bridge 446 
the captured genomic RNA with the assembling capsid. Some viruses, such as 447 
bacteriophage MS2 use their coat protein to package genomic RNA through specific signals 448 
(31, 32) but for complex, multi-layered capsid viruses, such as orbiviruses, genome 449 
packaging is likely to engage more than one viral protein. The two different kinds of 450 
interactions that are seen in BTV, VP6-VP3 and VP6-RNA, are consistent with this 451 
hypothesis.  452 
 453 
In contrast, RCAP analysis of the in vitro RNA-binding regions of reVP6, were largely not 454 
specific, a conclusion supported by the EMSA data. The amino terminal region (Re1) of 455 
reVP6 is also conserved among the Orbiviruses but changing the only positively-charged 456 
residues in this region, KR14-5, did not influence virus replication suggesting this conservation 457 
of amino acid sequence is due to other functional reasons. The disorder prediction of VP6 458 
structure showed that the N-terminal part of VP6 was more disordered than the C-terminal 459 
part, suggesting the N-terminus is highly mobile with non-specifc binding while the C-460 
terminus with a conserved function, which was consistent with our findings (33). Previous 461 
study suggested that only hexameric form of VP6 could perform helicase activity in vitro, 462 
although monomeric VP6 could still bind RNA (14, 16). However, it is still not known what 463 
form of VP6 exists within the viral capsid and in cells when it functions as an RNA binding 464 
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protein. The relationship between VP6 oligomerization and its different functions required 465 
further investigation.     466 
 467 
One region revealed by the comparative RCAP analysis (aa246-257; amino acid sequence: 468 
KKLLSMIGGVERK) was associated with RNA binding both in vitro and in the viral capsid. 469 
This region has two sites, each with two positively-charged residues, KK246-7 and RK257-8 and 470 
both were shown to be essential for viral replication. The same mutations led to VP6 losing 471 
its preference for BTV RNA in completion binding assays suggesting the region is part of 472 
discriminatory mechanism which selects BTV RNA over the cellular pool. This observation of 473 
preferential binding could be due to the region of VP6 recognizing certain sequences or 474 
secondary structures in the viral RNA segments. However, the precise sequence(s) that VP6 475 
binds during packaging and if VP6 plays an active role in the RNA complex formation remain 476 
to be investigated.  477 
 478 
In an earlier report, a cell-free assembly assay was established whereby the sequential 479 
mixing of replicase proteins VP1, VP4, and VP6, together with BTV ssRNAs, followed by the 480 
sequential addition of the inner capsid proteins VP3 and VP7, resulted in the successful 481 
packaging of ssRNAs into a core structure (5). In the absence of VP6 during sequential 482 
assembly packaging of ssRNAs is not observed, again consistent with a role for VP6 in the 483 
packaging of ssRNA into the BTV core structure. When a single cycle infection assay was 484 
performed with the RK257-8 mutant virus, amplified in a helper cell line, despite still being able 485 
to synthesize positive-sense viral ssRNAs, only low levels of negative-sense RNAs were 486 
detected, insufficient to support viral rescue. These data may indicate a marginal VP6 487 
activity, below the threshold required for growth or the residual activity of the VP6 488 
incorporated form the BSR-VP6 cell used for mutant virus recovery. These data clearly 489 
indicate that VP6 is critical in an early function, such as selectively binding to BTV RNA, and 490 
that the region encompassing aa246-257 is a required motif.  491 
 492 
Viral protein helps RNA virus to package correctly its genome through diverted mechanism. 493 
Besides the bacteriophage coat protein mentioned above, dsRNA bacteriophages of the 494 
Cystoviridae family contains a hexametic ATPase, P4, serves as RNA packaging motor (34, 495 
35). Recently, alphatetravirus was found to have a small encapsidated protein P17 that 496 
specifically binds to viral RNA and assist RNA packaging (36). Orbivirus VP6, despite some 497 
similarities with other packaging proteins, appears to have its unique mechanism.  498 
 499 
Previous study have suggested ATPase motif and helicase motif of VP6 based on in vitro 500 
functional analysis (14). K110, the previously reported ATPase motif, was in the RCAP 501 
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identified RNA binding region (Re2). However, changing this site also did not influence virus 502 
replication. E157, a site in the previously suggested helicase (DEAD box) also did not show 503 
any influence on virus grow (unpublished observation). Both these two sites are conserved 504 
within BTV but not shared with EHDV or AHSV. Studies have shown that ATP-driven duplex 505 
unwinding function is not necessarily the primary mechanism of helicase proteins (37, 38). 506 
Helicase protein can serve as translocator without unwinding the duplex (39-42). Further 507 
investigation is required to clarify the role of ATPase and helicase activity of VP6 during 508 
genome packaging. 509 
It is highly likely that RNA segments interact with each other in a sequential manner prior to 510 
the RNA complex packaging into capsid (1, 5, 15). In our recent report we showed that the 511 
RNA segments assortment is mainly based on RNA-RNA interactions via specific sequences 512 
(43). It is possible that VP6 may also be actively involved in assortment, but our current data 513 
does not support this notion.  514 
 515 
Structural analysis showed that VP1 and VP4 could be encapsidated within the core-like 516 
particles of VP3 and VP7, whilst VP6 alone could not be encapsidated without viral RNA (7). 517 
It can be hypothesized that not only is VP6 essential for genome packaging, but also, 518 
perhaps reciprocally, that genomic RNA plays a role in VP6 encapsidation. More detailed 519 
structural and functional studies are required to elucidate further the protein-RNA 520 
arrangements in the viral capsid, and precisely how these interactions promote genome 521 
packaging during capsid assembly. 522 
 523 
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FIGURE LEGENDS 540 
 541 
Figure 1.   RNA packaging in viral particles relied on VP6. (A) VP6 truncated virus was 542 
used to infect BSR or BSR-VP6 cells, 12 hours later the viral particles were harvested and 543 
purified, and the positive (+) and negative (-) strand, representing genomic ssRNA and 544 
dsRNA respectively, were measured by qRT-PCR. (B) BTV ssRNAs in the cell lysate from 545 
(A) were measured by qRT-PCR (C) CFA assay was performed in original method (control), 546 
in absence of VP6 (no VP6), or adding VP6 at later time point (late VP6 adding). The 547 
assembled complex was purified and packaged and viral RNA measured by qRT-PCR. The 548 
mean values ±SD are shown (n=3). 549 
 550 
Figure 2. Regions of the BTV VP6 that contacts RNA.  The grey bar represents the VP6 551 
protein, with the vertical dashes denoting the positions of positively and negatively-charged 552 
amino acids. The thick black lines represent peptides identified in the RCAP analyses 553 
performed with recombinant VP6 protein (reVP6) and either single-stranded or double-554 
stranded RNAs and from purified cores. Details of the peptides are presented in Table 1. 555 
The three regions in reVP6 contact RNAs are named Re1-3. Regions in the core-associated 556 
VP6 that contact packaged genomic RNAs are named Ca1-4. Mutations were introduced on 557 
13 specific charged sites (number 1-13) and the sites that mutations had lethal effect 558 
indicated (*).  559 
 560 
Figure 3.  Plaque formations of WT and mutant viruses. 561 
 562 
Figure 4.  Mutant VP6 express similar to WT VP6. Four mutants (RK246-7AA, RK246-7EE, 563 
RK257-8AA and RK257-8EE) and wild type (WT) VP6 encoding S9 RNAs were used to transfect 564 
BSR cells. Protein expression and localization were monitored by immunofluorescence 565 
staining and confocal microscopy. Green: VP6; blue: Hoechst staining.  566 
 567 
Figure 5.  Conformational analysis of mutant reVP6. (A) Five mutant reVP6 protein were 568 
expressed in E. coli and analyzed by SDS-PAGE together with wild type (WT) VP6, followed 569 
by coomassie blue staining. The sizes of protein ladder (M) are indicated. (B) The figure 570 
shows CD spectra of VP6 mutants normalized to wild type VP6. Each mutant and wild-type 571 
VP6 are indicated with different colours. 572 
 573 
Figure 6.  VP6 shows BTV RNA binding preference. (A) Two mutant VP6 protein, RK208-574 
9EE and RK257-8EE, together with WT VP6, were incubated with 
32P-labelled BTV S10 575 
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ssRNA for interaction. The shifting of the VP6-RNA complex was subjected to EMSA using 576 
0.8% agarose gel and TBE buffer before being analysed with phosphorimager. (B) WT or 577 
RK257-8EE reVP6 were bound to Ni-beads and incubated with BTV ssRNA S10, in absence 578 
or presence of 100 folds quantity of tRNA (+tRNA). The bound RNA was then eluted and 579 
quantified with qRT-PCR. The mean values ±SD are shown (n=3). 580 
 581 
Figure 7. Mutations in Ca2/Re3 region destroys BTV RNA preferential binding. 582 
Competition assay was performed using 1µg of WT (A), RK257-8AA (B), KK246-7AA (C), or 583 
RK208-9EE reVP6 (D) and 0.1µg of 
32P-labelled BTV S10. Xenopus elongation factor (Xef) 584 
mRNA was added in quantities as indicated. The free S10 RNA size is indicated.  585 
 586 
Figure 8.  Mutation on VP6 prohibits genomic RNA packaging. CFA assay was 587 
performed in the presence of WT VP6 (control), RK257-8EE VP6, or in absence of VP6 (no 588 
VP6). The assembled complex was purified and the packaged viral RNA measured by qRT-589 
PCR. The mean values ±SD are shown (n=3). 590 
 591 
Figure 9.  VP6 mutant virus is deficient in producing dsRNA genome. The VP6 RK257-592 
8EE mutant virus was used to infect BSR cells (RK257-8EE, red line) or BSR-VP6 cells (WT, 593 
blue line). Total cytoplasmic RNA was harvested at 0, 2, 4, and 6 hpi. The positive (+) and 594 
negative (-) strand RNA representing genomic ssRNA (left panel) and dsRNA (right panel) 595 
respectively, were measured by qRT-PCR. The mean values ±SD are shown (n=3). 596 
 597 
 598 
 599 
  600 
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Table 1.  Characteristics of the VP6 peptides assigned to contact RNA. 
Sample M/Z 
Error 
(ppm) 
Assign.
Confid. 
(%)  Peptide sequence AA # Modifications 
Fold 
above  
no HCHO 
reVP6/ssRNA 655.39 4.7 97.8& SAAILLAPGDVIK 2-14 Acetylation, N-term  >10* 
reVP6/ssRNA 733.44 4.6 100 SAAILLAPGDVIKR 2-15 Acetylation, N-term  >10 
reVP6/dsRNA 557.80 4.4 100 IHTAVGSGSGTK 83-94 None >10 
reVP6/ssRNA & reVP6/dsRNA 851.90 5.3 100 VGGGGGDADAGVGATGTNGGR 111-131 None >10, 5.6 
reVP6/ssRNA 608.34 0.5 100 WVVLTEEIAR 132-141 None >10 
Core/dsRNA 682.03 0.4 100 IDVYRDEVPAQIIEVER 151-167 None >10 
Core/dsRNA 789.68 2.4 100 IDVYRDEVPAQIIEVERSLQKELGISR 151-177 None >10 
Core/dsRNA 699.37 0.4 100 DEVPAQIIEVERSLQKELGISR 156-177 None >10 
reVP6/ssRNA & dsRNA 795.37 -3.6 100 EGVEEEKTSEEPAR 221-234 None >10 
reVP6/ssRNA & dsRNA 646.35 3.5 100 IGITIEGVMSQK 235-246 Oxidation of M9 >10 
reVP6/ssRNA & dsRNA 545.80 1.6 100 GVMSQKKLLSMIGGVERKMA 241-260 Oxidation of M11 >10 
reVP6/ssRNA, dsRNA, & Core 609.85 1.7 100 KLLSMIGGVER 247-257 Oxidation of M5 >10 
reVP6/ssRNA & dsRNA 545.80 2.2 100 LLSMIGGVER 248-257 Oxidation of M4 5.2, 5.2 
reVP6/ssRNA & dsRNA 647.34 1.3 100 ESAVMLVSNSIK 266-277 Oxidation of M5 >10 
reVP6/ssRNA & dsRNA 588.32 1.5 100 ESAVMLVSNSIKDVVR 266-281 Oxidation of M5 >10 
reVP6/ssRNA & dsRNA 554.94 -0.1 100 ATAYFTAPTGDPHWK 282-296 None >10 
Core/dsRNA 706.69 -1.6 83.9 ATAYFTAPTGDPHWKEVAR 282-300 None >10 
Core/dsRNA 669.85 0.1 100 NILAYTSTGGDVK 307-319 None >10 
Core/dsRNA 784.89 -0.8 100 NILAYTSTGGDVKTE 307-321 None >10 
Core/dsRNA 853.12 1.1 100 NILAYTSTGGDVKTEFLHLIDHL 307-329 None >10 
reVP6/ssRNA 473.94 4.5 100 IGITIEGVMSQKK 235-247 None >10 
reVP6/ssRNA 609.85 -2.6 82.9 LLSMIGGVERK 248-258 None >10 
reVP6/ssRNA 558.82 2.9 93.5 VSNSIKDVVR 272-281 None >10 
&Confidence of peptide assignment from collision-induced peptide fragmentation.  
*The area of the peptide peak relative to the area in the reaction performed without formaldehyde.   
 o
n
 January 4, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
 Table 2.  Conformational analysis of mutant reVP6.  
VP6 Helix /loop (%) 
(α, π, 3,10 helix, loop) 
Beta strands (%) Turn (%) RMSD 
WT 48.0 36.6 15.5 0.0467 
R167E 47.7 37.0 15.3 0.0499 
R177E 47.3 37.1 15.5 0.0506 
RK208-9EE 47.4 37.2 15.5 0.0493 
RK257-8EE 47.8 36.8 15.4 0.0478 
KRR303-5EEE 47.3 37.3 15.4 0.0486 
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